Literature DB >> 18485083

Delayed adverse vascular events after splenectomy in hereditary spherocytosis.

R F Schilling1, R E Gangnon, M I Traver.   

Abstract

BACKGROUND: It is probable that the variety and frequency of delayed adverse vascular events after splenectomy are underappreciated. Splenectomy is performed for a wide variety of conditions, and delayed postsplenectomy hazards are not often studied.
OBJECTIVE: To estimate the relative risk of adverse vascular events in members of hereditary spherocytosis families who have or have not had a splenectomy.
METHODS: Members of families in which hereditary spherocytosis exists were systematically questioned about adverse vascular events.
RESULTS: The cumulative incidence of arterial and venous events at age 70 years was greater in persons who had undergone a splenectomy for spherocytosis (arterial, 22% females, 32% males; venous, 20% females, 19% males) than in affected persons who did not undergo splenectomy (arterial, 3% females, 2% males; venous, 6% females, 4% males) or non-affected family members (arterial, 10% females, 17% males; venous, 4% females, 12% males). Affected subjects who undergo splenectomy are at greatly increased risk of arterial events as compared to affected subjects who do not undergo splenectomy [arterial, hazard ratio (HR) 7.2, 95% confidence interval (CI) 2.8-17.2; venous, HR 3.3, 95% CI 1.1-9.8].
CONCLUSION: There is a significant, long-lasting, increased risk of adverse arterial and venous thromboembolic events after splenectomy performed for hereditary spherocytosis. A review of the literature indicates that this is also true when splenectomy is performed for several other indications.

Entities:  

Mesh:

Year:  2008        PMID: 18485083     DOI: 10.1111/j.1538-7836.2008.03024.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  31 in total

1.  Long-term follow-up of subtotal splenectomy for hereditary spherocytosis: a single-center study.

Authors:  Thomas Pincez; Corinne Guitton; Frédéric Gauthier; Guénolée de Lambert; Véronique Picard; Madeleine Fénéant-Thibault; Ali Turhan; Narla Mohandas; Gil Tchernia; Loïc Garçon
Journal:  Blood       Date:  2016-01-15       Impact factor: 22.113

Review 2.  Abnormalities of the erythrocyte membrane.

Authors:  Patrick G Gallagher
Journal:  Pediatr Clin North Am       Date:  2013-10-15       Impact factor: 3.278

Review 3.  Sickle cell disease and venous thromboembolism: what the anticoagulation expert needs to know.

Authors:  Rakhi P Naik; Michael B Streiff; Sophie Lanzkron
Journal:  J Thromb Thrombolysis       Date:  2013-04       Impact factor: 2.300

Review 4.  Pulmonary complications of sickle cell disease.

Authors:  Andrew C Miller; Mark T Gladwin
Journal:  Am J Respir Crit Care Med       Date:  2012-03-23       Impact factor: 21.405

5.  Splenectomy revisited in 2011: Impact on hematologic toxicities while performing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.

Authors:  Nancy Deslauriers; Harold Olney; Rami Younan
Journal:  J Gastrointest Oncol       Date:  2011-06

6.  Persistent changes in circulating white blood cell populations after splenectomy.

Authors:  Minke A E Rab; Aafke Meerveld-Eggink; Heleen van Velzen-Blad; Douwe van Loon; Ger T Rijkers; Okke de Weerdt
Journal:  Int J Hematol       Date:  2017-09-26       Impact factor: 2.490

Review 7.  Splenectomy for immune thrombocytopenia: down but not out.

Authors:  Shruti Chaturvedi; Donald M Arnold; Keith R McCrae
Journal:  Blood       Date:  2018-01-02       Impact factor: 22.113

Review 8.  Red blood cells in thrombosis.

Authors:  James R Byrnes; Alisa S Wolberg
Journal:  Blood       Date:  2017-08-15       Impact factor: 22.113

Review 9.  Pleiotropic effects of intravascular haemolysis on vascular homeostasis.

Authors:  Gregory J Kato; James G Taylor
Journal:  Br J Haematol       Date:  2009-12-01       Impact factor: 6.998

Review 10.  Vascular complications after splenectomy for hematologic disorders.

Authors:  Shelley E Crary; George R Buchanan
Journal:  Blood       Date:  2009-07-27       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.